A Form 4 filed on September 23, 2026 discloses that Ronnie Duane Clark, a director of Inmune Bio, Inc. (NASDAQ:INMB), was awarded 100,000 stock options on September 15, 2026 as an initial grant in connection with his service on the company's board.

Key Highlights

  • Reporting person: Ronnie Duane Clark, identified as a Director of Inmune Bio, Inc.
  • Grant date: September 15, 2026, with an expiration date of September 14, 2036.
  • Options awarded: 100,000 stock options (transaction code A - acquired) with an exercise price of $2.33 per share.
  • Price paid: $0 for the derivative securities at the time of grant.
  • Vesting schedule: Options vest in 36 equal monthly installments over three years, beginning one month after the grant date, reaching 100% on the three-year anniversary.
  • Plan: Granted under the issuer's Third Amended and Restated 2021 Stock Incentive Plan.
  • Beneficial ownership following transaction: 100,000 derivative securities held directly.

INmune Bio Director Clark Granted Initial Board Option Award

According to the filing, Ronnie Duane Clark, a director at Inmune Bio, Inc., received an initial award of 100,000 stock options on September 15, 2026. The filing describes these as granted "in consideration for the Reporting Person's service to the Board of Directors of INmune Bio, Inc." The options were issued under the company's Third Amended and Restated 2021 Stock Incentive Plan, with an exercise price of $2.33 per share and an expiration date of September 14, 2036.

The filing reports that the options will vest in 36 equal monthly installments over a three-year period, beginning one month after the grant date. Full vesting, the filing states, "shall occur on the three-year anniversary of the date of grant." No cash consideration was paid by Clark for the option grant, as the price of the derivative security is listed as $0. Following the transaction, Clark's reported beneficial ownership of derivative securities stands at 100,000 stock options, held directly.

The Form 4 was signed by R. Duane Clark and filed with the SEC on September 23, 2026, covering the transaction dated September 15, 2026. No non-derivative securities transactions were reported in Table I of the filing.

What Was Disclosed

The filing reports a single acquisition of 100,000 stock options by director Ronnie Duane Clark in Inmune Bio, Inc. at an exercise price of $2.33, expiring September 14, 2036, granted as an initial board service award with a three-year monthly vesting schedule.